Ru Zhou1,2,3, Ping Ma4, Aiqin Xiong4, Yehua Xu4, Yang Wang4, Qingbin Xu4. 1. Department of Pharmacology, School of Pharmacy, Ningxia Medical University, Yinchuan, China. 2. Key Laboratory of Hui Ethnic Medicine Modernization, Ministry of Education, Ningxia Medical University, Yinchuan, China. 3. Ningxia Hui Medicine Modern Engineering Research Center and Collaborative Innovation Center, Ningxia Medical University, Yinchuan, China. 4. Department of Cardiology, General Hospital of Ningxia Medical University, Yinchuan, China.
Abstract
AIMS: Cardiovascular disease is the leading cause of death with high morbidity and mortality, and chronic heart failure is the terminal phase of it. This study aimed to investigate the protective effects of the low-dose rosuvastatin on isoproterenol-induced chronic heart failure and to explore the possible related mechanisms. METHODS: Male Sprague Dawley rats were given isoproterenol 5 mg/kg once a day for 7 days to establish heart failure model by subcutaneous injection. Simultaneously, low-dose rosuvastatin (5 mg/kg) was orally administrated from day 1 to day 14. Protective effects were evaluated by hemodynamic parameter, histopathological variables, serum asymmetric dimethylarginine (ADMA), cardiac troponin I (cTnI), brain natriuretic peptide (BNP) and myocardial nitric oxide (NO), and the levels of dimethylarginine dimethylaminohydrolase 2 (DDAH2), arginine methyltransferases 1 (PRMT1) and endothelial nitric oxide synthase (eNOS) expression were analyzed. RESULTS: Therapeutic rosuvastatin (5 mg/kg) significantly attenuated isoproterenol-induced hypertrophy, remodeling and dysfunction of ventricle, reduced the increased serum content of ADMA, cTnI, and BNP, and elevated myocardial NO in rats (P<.05). Besides, rosuvastatin also significantly inhibited fibrosis of myocardium, normalized the increased PRMT1 and decreased DDAH2 expression. CONCLUSIONS: Low-dose rosuvastatin exerted cardioprotective effects on isoproterenol-induced heart failure in rats by modulating DDAH-ADMA-NO pathway, and it may present the new therapeutic value in ameliorating chronic heart failure.
AIMS: Cardiovascular disease is the leading cause of death with high morbidity and mortality, and chronic heart failure is the terminal phase of it. This study aimed to investigate the protective effects of the low-dose rosuvastatin on isoproterenol-induced chronic heart failure and to explore the possible related mechanisms. METHODS: Male Sprague Dawley rats were given isoproterenol 5 mg/kg once a day for 7 days to establish heart failure model by subcutaneous injection. Simultaneously, low-dose rosuvastatin (5 mg/kg) was orally administrated from day 1 to day 14. Protective effects were evaluated by hemodynamic parameter, histopathological variables, serum asymmetric dimethylarginine (ADMA), cardiac troponin I (cTnI), brain natriuretic peptide (BNP) and myocardial nitric oxide (NO), and the levels of dimethylarginine dimethylaminohydrolase 2 (DDAH2), arginine methyltransferases 1 (PRMT1) and endothelial nitric oxide synthase (eNOS) expression were analyzed. RESULTS: Therapeutic rosuvastatin (5 mg/kg) significantly attenuated isoproterenol-induced hypertrophy, remodeling and dysfunction of ventricle, reduced the increased serum content of ADMA, cTnI, and BNP, and elevated myocardial NO in rats (P<.05). Besides, rosuvastatin also significantly inhibited fibrosis of myocardium, normalized the increased PRMT1 and decreased DDAH2 expression. CONCLUSIONS: Low-dose rosuvastatin exerted cardioprotective effects on isoproterenol-induced heart failure in rats by modulating DDAH-ADMA-NO pathway, and it may present the new therapeutic value in ameliorating chronic heart failure.
Authors: Isadora Prado Cano; Thiago José Dionisio; Tânia Mary Cestari; Adriana Maria Calvo; Bella Luna Colombini-Ishikiriama; Flávio Augusto Cardoso Faria; Walter Luiz Siqueira; Carlos Ferreira Santos Journal: PLoS One Date: 2019-05-22 Impact factor: 3.240
Authors: Gabriel Komla Adzika; Hongjian Hou; Adebayo Oluwafemi Adekunle; Ruqayya Rizvi; Joseph Adu-Amankwaah; Wenkang Shang; Kexue Li; Qi-Ming Deng; Richard Mprah; Marie Louise Ndzie Noah; Hong Sun Journal: Front Cardiovasc Med Date: 2021-11-25
Authors: Dalia I Hamdan; Samia S Hafez; Wafaa H B Hassan; Mai M Morsi; Heba M A Khalil; Yasmine H Ahmed; Omar A Ahmed-Farid; Riham A El-Shiekh Journal: RSC Adv Date: 2022-01-26 Impact factor: 3.361